Quantbot Technologies LP Has $1.44 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Quantbot Technologies LP decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 65.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,328 shares of the company’s stock after selling 8,276 shares during the quarter. Quantbot Technologies LP’s holdings in Medpace were worth $1,438,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Pallas Capital Advisors LLC lifted its stake in shares of Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after buying an additional 2,101 shares during the last quarter. Barclays PLC lifted its position in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in shares of Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after acquiring an additional 844 shares during the period. Loomis Sayles & Co. L P grew its position in shares of Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock valued at $68,696,000 after purchasing an additional 13,880 shares during the last quarter. Finally, Cerity Partners LLC increased its stake in shares of Medpace by 18.7% during the third quarter. Cerity Partners LLC now owns 61,890 shares of the company’s stock worth $20,659,000 after purchasing an additional 9,741 shares during the period. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on MEDP shares. Leerink Partners initiated coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 price objective on the stock. Robert W. Baird boosted their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Eight equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and a consensus price target of $376.30.

Medpace Stock Performance

Shares of NASDAQ MEDP opened at $330.59 on Tuesday. The company’s 50 day moving average price is $337.29 and its 200-day moving average price is $339.65. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The company has a market capitalization of $10.07 billion, a P/E ratio of 26.17, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.